Mankhwala Atsopano Ofufuza Odwala Acute Myeloid Leukemia

A GWIRITSANI KwaulereKutulutsidwa 3 | eTurboNews | | eTN
Avatar ya Linda Hohnholz
Written by Linda Hohnholz

Priothera Ltd. lero yalengeza kuti bungwe la US Food and Drug Administration (FDA) lapereka chilolezo kuti lipitilize kufunsira kwa Company Investigational New Drug (IND) kuti iyambe maphunziro ake ofunikira a Phase 2b/3 pa mocravimod (wotchedwa MO-TRANS).

Priothera adzayambitsa maphunziro a MO-TRANS Global Phase 2b/3 ku Europe, US ndi Japan, ndikuwunika mphamvu ndi chitetezo cha mocravimod ngati chithandizo chothandizira komanso chothandizira odwala Acute Myeloid Leukemia (AML) omwe akudwala allogenic hematopoietic stem cell transplant (HSCT) ). Kafukufuku wa MO-TRANS akuyembekezeka kuyamba mu theka lachiwiri la 2022 ndipo zoyambira za kafukufukuyu zikuyembekezeka kumapeto kwa 2024.

Allogenic stem cell transplantation ndiyo njira yokhayo yomwe ingathe kuchiritsa odwala a AML, komabe njira zochiritsira zamakono zimagwirizanabe ndi zotsatira zambiri, komanso chiwerengero cha imfa. 

Florent Gros, Co-Founder ndi CEO wa Priothera, anati "Chilolezo cha FDA IND kuyambitsa kafukufuku wa MO-TRANS kuyesa mocravimod mwa odwala a AML omwe akudwala allogeneic HSCT ndi chinthu china chofunika kwambiri kwa Priothera. Tili pachiwopsezo choyambitsa mayeso ofunikirawa a Phase 2b/3 ndipo tikuyembekezera kugwira ntchito limodzi ndi gulu lalikulu la ofufuza achangu ku US, Europe ndi Asia, omwe ali ndi cholinga chobweretsa mocravimod kwa odwala ngati chithandizo chothandizira komanso kukonza. kwa AML komanso matenda ena a hematologic.

Ponena za wolemba

Avatar ya Linda Hohnholz

Linda Hohnholz

Mkonzi wamkulu kwa eTurboNews zochokera ku eTN HQ.

Amamvera
Dziwani za
mlendo
0 Comments
Zolowetsa Pamakina
Onani ndemanga zonse
0
Mukufuna malingaliro anu, chonde yankhani.x
Gawani ku...